Christel Fontaine

Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

Marleen Keyaerts, Catarina Xavier, Johannes Heemskerk et al. · Journal of Nuclear Medicine · 2015 · 419 citations · Full text

Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports

Jo Caers, Christel Fontaine, Vincent Vinh‐Hung et al. · Supportive Care in Cancer · 2004 · 177 citations

Pulmonary Embolism, Thrombosis, Venous Thrombosis +10

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

Ahmad Awada, Fátima Cardoso, Christel Fontaine et al. · European Journal of Cancer · 2007 · 152 citations

Advanced Breast Cancer, Breast Oncology, Oncology +6

Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients

Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers et al. · Journal of Nuclear Medicine · 2020 · 116 citations · Full text

Breast Oncology, Healthy Subjects, Tumor Biology +18

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

Patrick Schöffski, Jean‐Yves Blay, Jacques De Grève et al. · European Journal of Cancer · 2010 · 109 citations

Oncology, Medicine, Pathology +9